Daily Anesthesiology Research Analysis
Three impactful ICU/anesthesiology-adjacent studies stood out: a translational sepsis study links hypocholesterolemia to cardiomyocyte membrane cholesterol loss and catecholamine hyporesponsiveness, reversible by cholesterol infusion; a 30-country prospective cohort maps real-world platelet transfusion practices and variability; and a multicenter study shows molecular syndromic panels for VABP alter antibiotic decisions without harming mortality.
Summary
Three impactful ICU/anesthesiology-adjacent studies stood out: a translational sepsis study links hypocholesterolemia to cardiomyocyte membrane cholesterol loss and catecholamine hyporesponsiveness, reversible by cholesterol infusion; a 30-country prospective cohort maps real-world platelet transfusion practices and variability; and a multicenter study shows molecular syndromic panels for VABP alter antibiotic decisions without harming mortality.
Research Themes
- Translational mechanisms in sepsis cardiomyopathy
- ICU platelet transfusion stewardship and variability
- Rapid molecular diagnostics in ventilator-associated pneumonia
Selected Articles
1. Sepsis-induced hypocholesterolemia is linked to low cardiomyocyte membrane cholesterol and impaired catecholamine responsiveness.
In septic patients and a parallel rat model, HDL-cholesterol fell early and predicted worse outcomes, while cardiomyocyte membrane cholesterol decreased with blunted dobutamine responsiveness. Cholesterol infusion (HDL or liposomal) restored membrane cholesterol, adrenergic signaling, and inotrope responsiveness, revealing a mechanistic link between hypocholesterolemia and catecholamine hyporesponsiveness.
Impact: This rigorous translational study identifies a reversible membrane-level mechanism for sepsis-induced catecholamine hyporesponsiveness, suggesting a novel therapeutic avenue via cholesterol repletion.
Clinical Implications: Consider monitoring lipoproteins (especially HDL-C) as part of sepsis cardiomyopathy risk stratification and explore cholesterol repletion strategies to restore vasopressor/inotrope responsiveness, pending clinical trials.
Key Findings
- Early decreases in HDL-cholesterol in septic patients and rats predicted worse outcomes.
- Cardiomyocyte membrane cholesterol decreased with blunted dobutamine inotropic response, consistent with sepsis-induced cardiomyopathy.
- Cholesterol infusion (HDL or liposomal) restored membrane cholesterol, adrenergic signaling, and dobutamine responsiveness.
Methodological Strengths
- Integrated human ICU data with a longitudinal, physiologically relevant rat sepsis model.
- Mechanistic intervention (cholesterol infusion) demonstrated reversibility and supported causality.
Limitations
- Human sample size was modest and non-randomized; interventional effects were shown in animals, not yet in clinical trials.
- Generalizability and safety of cholesterol infusion require prospective human validation.
Future Directions: Conduct randomized clinical trials testing cholesterol repletion strategies in septic shock with catecholamine hyporesponsiveness, and evaluate lipid phenotype-guided therapy.
BACKGROUND: Sepsis-induced cardiomyopathy (SIM) is characterized by myocardial dysfunction, diminished catecholamine responsiveness and worse outcomes. Hypocholesterolemia is also a well-recognized prognosticator of poor outcomes in sepsis. In vitro physiology/pharmacology studies indicate that low cholesterol levels within the cardiomyocyte membrane regulate ß-adrenergic receptor activity. We therefore hypothesized that cardiomyocyte membrane cholesterol levels are reduced in sepsis and this contributes to SIM. METHODS: Cardiovascular biomarkers and plasma lipid profiles measured sequentially (6, 24 and 72 h) in a fluid-resuscitated rat model of fecal peritonitis were compared against those measured in 27 septic patients on Days 1-3 of ICU admission. In separate studies, rat hearts were excised at the same time points for measurement of cardiomyocyte membrane cholesterol and downstream adrenergic signaling. In a final study, the impact of a 15-hour infusion of cholesterol, either given as HDL-cholesterol or liposomal cholesterol, commencing at 6 h post-sepsis induction, on dobutamine responsiveness and cardiomyocyte membrane cholesterol levels was assessed. RESULTS: The magnitude of fall in stroke volume, rise in heart rate, plasma troponin and BNP, and fall in plasma HDL-cholesterol on ICU Day 1 in septic patients and at 6 h in the rat model all prognosticated for poor outcomes. In parallel, cardiomyocyte membrane cholesterol fell in the rats, more so in poor prognosis animals, with a blunted inotropic response to dobutamine, indicative of SIM. Cholesterol administration restored cardiomyocyte membrane cholesterol, dobutamine responsiveness and adrenergic signaling. CONCLUSIONS: In a long-term rat model of sepsis, that parallels changes seen in septic patients, cardiomyocyte membrane cholesterol fell with associated decreases in catecholamine responsiveness. These features could be restored by cholesterol infusion, suggesting potential utility as a therapeutic.
2. Platelet Transfusion Practices in the ICU: A Prospective Multicenter Cohort Study.
In a 30-country, 233-center prospective cohort, 6% of ICU patients received platelet transfusions, mainly for active bleeding (42%) and prophylaxis (33%). Median pretransfusion platelet count was 44×10^9/L and threshold adherence varied, with 16% non-adherence and marked geo-economic variability, highlighting stewardship and standardization gaps.
Impact: Provides contemporary, globally generalizable data on platelet transfusion indications, thresholds, and adherence, essential for ICU transfusion stewardship and guideline refinement.
Clinical Implications: Use indication-specific thresholds, reduce non-adherence, and implement local stewardship protocols informed by regional practice patterns to optimize platelet use and safety.
Key Findings
- Platelet transfusions occurred in 6% (208/3643) of ICU patients.
- Main indications: active bleeding 42%, prophylaxis 33%, upcoming procedures 12%.
- Median pretransfusion platelet count was 44×10^9/L; stated transfusion thresholds had 16% non-adherence, with substantial regional variation and no transfusions reported from lower-middle-income sites.
Methodological Strengths
- Prospective, multinational cohort across 233 centers in 30 countries.
- Detailed capture of indications, thresholds, and adherence enabling benchmarking.
Limitations
- Observational design precludes causal inference on outcomes of different thresholds.
- Lower-middle-income regions underrepresented in transfusion events, limiting generalizability.
Future Directions: Develop and test standardized, indication-specific transfusion protocols with audit-feedback to improve adherence and assess patient-centered outcomes.
OBJECTIVE: There is a lack of comprehensive international data regarding platelet transfusion practices in the ICU. This study aimed to evaluate the current occurrence rate of platelet transfusion in the ICU and provide an overview of platelet transfusion practices including indications for a platelet transfusion, thresholds, (non-)adherence and geo-economic region variations. DESIGN: International prospective cohort study. SETTING: Two hundred thirty-three centers in 30 countries worldwide. PATIENTS: All patients 18 years old and older, admitted to the ICU during a single study week, selected by each site from one of the 16 predefined weeks (March 2019 to October 2022), were included. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Of the 3643 patients, 208 (6%) received a platelet transfusion during their ICU stay and main indications consisted of active bleeding (42%, n = 187/443), prophylaxis (33%, n = 144/443) or an upcoming procedure (12%, n = 51/443). The median platelet count before transfusion was 44 × 10 9 /L (interquartile range [IQR], 20-78) with variation by indication, including a higher median of 60 × 10 9 /L (IQR 31-93) during active bleeding. A threshold for transfusion was stated in 51% ( n = 224/443) of the events, with a median threshold platelet count of 50 × 10 9 /L (IQR, 40-100). The advised threshold was not adhered to in 16% ( n = 36/224) of cases, with the majority having active bleeding as indication. Contrasts in transfusion practices were observed across different geo-economic regions. Platelet transfusions were administered to 6% ( n = 156/2520) of patients in high-income countries, 5% ( n = 52/1069) of patients in upper-middle-income countries and in none from lower-middle-income countries ( n = 0/54). Non-adherence was higher in the high-income countries (23%, n = 34/149) than upper-middle-income countries (3%, n = 2/75). CONCLUSIONS: Platelet transfusions were administered to a small proportion of critically ill patients, and were given to treat active bleeding or as prophylaxis in the majority of cases. Occurence rate, indication and threshold adherence for platelet transfusion widely varied between geo-economic regions.
3. Use of a molecular syndromic panel for the etiological diagnosis of ventilator-associated bacterial pneumonia: impact on clinical outcomes and antibiotic use from a multicenter, prospective study.
In 237 VABP patients across multiple centers, deploying a molecular syndromic panel influenced antibiotic choices without adverse effects on mortality. Higher SOFA scores independently associated with mortality, and prior carbapenem-resistant organism isolation signaled risk, underscoring stewardship potential and need for longer-term evaluation.
Impact: Demonstrates real-world clinical impact of rapid molecular diagnostics on antibiotic decision-making in VABP without compromising mortality, supporting stewardship-focused implementation.
Clinical Implications: Integrate syndromic panels to refine empiric-to-targeted antibiotic transitions in VABP, with concurrent stewardship oversight and local epidemiology alignment.
Key Findings
- Use of a molecular syndromic panel influenced antibiotic decisions in VABP.
- No unfavorable effect on mortality was observed with panel-guided management.
- SOFA score independently associated with mortality; prior carbapenem-resistant organism isolation signaled higher risk.
Methodological Strengths
- Multicenter prospective observational design in a real-world ICU setting.
- Assessment of both clinical outcomes and antimicrobial stewardship endpoints.
Limitations
- Observational design with potential confounding and incomplete long-term outcomes.
- Details on specific resistant organisms and time-to-appropriate therapy not fully detailed in the abstract.
Future Directions: Randomized or stepped-wedge evaluations to quantify effects on time-to-appropriate therapy, resistance emergence, and antibiotic days, with cost-effectiveness analyses.
BACKGROUND: Ventilator-associated bacterial pneumonia (VABP) is a common infection in critically ill patients in intensive care units (ICU), with attributable mortality of up to 13%, and its etiological diagnosis remains challenging. MATERIALS AND METHODS: We conducted a multicenter, prospective, observational study within the MULTI-SITA platform to assess the impact on relevant clinical and antimicrobial stewardship outcomes of the use of a molecular syndromic panel (BIOFIRE® FILMARRAY® Pneumonia RESULTS: Overall, 237 patients with VABP were included in the study. In multivariable analysis, SOFA score (hazard ratio [HR] 1.13, 95% confidence interval [CI] 1.04–1.22, p = 0.003), previous isolation of carbapenem-resistant CONCLUSION: The use of a molecular syndromic panel in patients with VABP was able to impact antibiotic decisions, without an unfavorable effect on mortality. Further study is necessary to assess the long-term effects in terms of antimicrobial stewardship of molecular syndromic panels-based antibiotic treatment decisions. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13054-025-05632-z.